Voyager Q4 2025 net loss $27.4M, cash $201.7M; key pipeline milestones H2 2026

Voyager Therapeutics, Inc.

Q4 2025 net loss $27.4M vs $34.5M in Q4 2024; full year net loss $119.7M vs $65.0M.
Collaboration revenue Q4 $15.3M (up 143% YoY) but full year $40.4M (down 50% YoY).
Cash $201.7M at Dec 31 2025; runway expected into 2028 with up to $2.4B in milestone potential.
VY1706 (tau-silencing) IND planned Q2 2026, first-in-human dosing H2 2026; VY7523 tau PET data H2 2026.
APOE gene therapy program paused; Neurocrine milestone $3M triggered in Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.